Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
MWN-AI** Summary
Lantheus Holdings, Inc. announced on March 2, 2026, that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA® (lutetium Lu 177 dotatate). This marks a significant achievement for Lantheus as it strives to enhance treatment options for patients suffering from somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which encompass tumors from the foregut, midgut, and hindgut regions.
Mary Anne Heino, the CEO of Lantheus, emphasized the importance of this approval in expanding targeted radiopharmaceutical therapies for GEP-NET patients. As advancements in imaging and clinical guidelines improve diagnostic accuracy, the necessity for effective treatment options is growing. The tentative approval indicates that the FDA's review of the Abbreviated New Drug Application (ANDA) has met federal legal requirements, although full approval will depend on the expiration of a 30-month stay related to a Hatch-Waxman patent litigation scheduled for June 2026.
Lantheus licensed the exclusive global rights to PNT2003 from POINT Biopharma Global, Inc. in December 2022. Notably, POINT was acquired by Eli Lilly and Company in December 2023.
GEP-NETs represent a rare, often slow-growing category of cancer affecting the digestive system, with statistics indicating approximately 200,000 patients in the U.S. The disease frequently suffers from underdiagnosis, with patients experiencing substantial delays in receiving proper treatment.
Through its more than 70 years in the radiopharmaceutical industry, Lantheus remains dedicated to improving patient outcomes and plans to bring PNT2003 to market pending final FDA approval.
MWN-AI** Analysis
Lantheus Holdings, Inc. (NASDAQ: LNTH) recently secured FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a significant milestone being the first radioequivalent to LUTATHERA® for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This event positions Lantheus to capture a pivotal market share in the growing radiopharmaceutical sector, especially given the rising prevalence of GEP-NETs in the U.S., currently estimated at 200,000 patients.
The tentative approval indicates that Lantheus has met the necessary criteria under the Federal Food, Drug, and Cosmetics Act, paving the way for potential full approval after the expiration of the associated patent litigation stay in June 2026. This prolonged timeline could create volatility in Lantheus’s stock price as investors speculate on the final approval's certainty. It is essential for investors to remain vigilant regarding updates on the patent situation and potential market competition from other upcoming therapies.
Given its strong commitment to advancing treatments for GEP-NETs and its established track record in the radiopharmaceutical space, Lantheus may represent a compelling investment opportunity. However, investors should consider both the current competitive landscape—exacerbated by the acquisition of POINT Biopharma by Eli Lilly, which may drive additional clinical development efforts in this area—and the inherent risks involved in pharmaceutical approvals.
In conclusion, Lantheus’s strategic positioning and product pipeline, combined with the increasing demand for targeted therapies, suggest a positive trajectory for the company in the medium to long term. Investors should closely monitor developments surrounding PNT2003's final approval and related market dynamics while weighing the potential risks of their investment. Diversification within their portfolio can also help mitigate risks associated with this sector's volatility.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent1 version of LUTATHERA® (lutetium Lu 177 dotatate). LUTATHERA® is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.
“As the first radioequivalent to LUTATHERA to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP-NETs. This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies. As the leading radiopharmaceutical-focused company, we remain committed to meeting this growing demand and look forward to making PNT2003 available to patients pending final FDA approval,” said Mary Anne Heino, Chief Executive Officer of Lantheus.
The FDA tentative approval indicates that the FDA has completed its review of the ANDA and that it meets the requirements for approval under the Federal Food, Drug and Cosmetics Act. Full approval of the ANDA is subject to the expiration of the 30-month stay in June 2026, triggered in connection with a Hatch-Waxman patent litigation.
Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing transaction, please click here. POINT was acquired by Eli Lilly and Company in December 2023.
About GEP-NETs
Neuroendocrine tumors (NETs) are rare, often slow-growing cancers that can develop throughout the body. A subset known as gastroenteropancreatic NETs (GEP-NETs) affects the digestive system and pancreas and may be functional or non-functional depending on hormone activity.2 Over the last few decades, the incidence of GEP-NETs has increased significantly, with the prevalence in the U.S. estimated to be approximately 200,000 patients.3 Because GEP-NETs often grow slowly and cause non-specific symptoms, up to 50% are initially misdiagnosed, with patients waiting an average of 4.3 years from symptom onset to diagnosis.4,5
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements relating to the potential FDA full approval of PNT2003 and statements regarding Lantheus’ expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by their use of terms such as “forward,” “look” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements.
1The term radioequivalent is used to describe a radiopharmaceutical whose mechanism of action is determined to be equivalent to that of the reference product approved by the FDA, or a similar regulator outside of the US.
2Neuroendocrine Tumors. Cleveland Clinic. Published June 26, 2024. Accessed May 22, 2025. https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net
3Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320.
4Kolarova T, et.al. P-136 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability. Annals of Oncology, Volume 31, S134.
5Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017 Mar 13;189(10):E398-E404. doi: 10.1503/cmaj.160771. PMID: 28385820; PMCID: PMC5359105.
LUTATHERA® is a registered trademark of Novartis AG and/or its affiliates.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
FAQ**
How will the FDA tentative approval for PNT2003 impact Lantheus Holdings Inc. (LNTH) in both short-term and long-term revenue projections?
What are the expected competitive advantages of PNT2003 over LUTATHERA® for Lantheus Holdings Inc. (LNTH) once it receives full FDA approval?
Considering the increasing incidence of GEP-NETs, how does Lantheus Holdings Inc. (LNTH) plan to expand its market share in this therapeutic area?
What potential risks and challenges does Lantheus Holdings Inc. (LNTH) foresee regarding the Hatch-Waxman patent litigation affecting the full approval of PNT2003?
**MWN-AI FAQ is based on asking OpenAI questions about Lantheus Holdings Inc. (NASDAQ: LNTH).
NASDAQ: LNTH
LNTH Trading
5.96% G/L:
$76.85 Last:
1,151,249 Volume:
$72.56 Open:
